Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Controlling for drug dose in systematic review and meta-analysis: a case study of the effect of antidepressant dose.

Hansen RA, Moore CG, Dusetzina SB, Leinwand BI, Gartlehner G, Gaynes BN.

Med Decis Making. 2009 Jan-Feb;29(1):91-103. doi: 10.1177/0272989X08323298. Review.

2.

Antidepressants for people with epilepsy and depression.

Maguire MJ, Weston J, Singh J, Marson AG.

Cochrane Database Syst Rev. 2014 Dec 3;(12):CD010682. doi: 10.1002/14651858.CD010682.pub2. Review.

PMID:
25464360
3.

Antidepressant treatment for postnatal depression.

Molyneaux E, Howard LM, McGeown HR, Karia AM, Trevillion K.

Cochrane Database Syst Rev. 2014 Sep 11;(9):CD002018. doi: 10.1002/14651858.CD002018.pub2. Review.

PMID:
25211400
4.

Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis.

Amick HR, Gartlehner G, Gaynes BN, Forneris C, Asher GN, Morgan LC, Coker-Schwimmer E, Boland E, Lux LJ, Gaylord S, Bann C, Pierl CB, Lohr KN.

BMJ. 2015 Dec 8;351:h6019. doi: 10.1136/bmj.h6019. Review.

5.

Pharmacological interventions for somatoform disorders in adults.

Kleinstäuber M, Witthöft M, Steffanowski A, van Marwijk H, Hiller W, Lambert MJ.

Cochrane Database Syst Rev. 2014 Nov 7;(11):CD010628. doi: 10.1002/14651858.CD010628.pub2. Review.

PMID:
25379990
6.

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder.

Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS.

Ann Intern Med. 2005 Sep 20;143(6):415-26. Review.

PMID:
16172440
7.

Venlafaxine extended-release: a review of its use in the management of major depression.

Wellington K, Perry CM.

CNS Drugs. 2001;15(8):643-69. Review.

PMID:
11524036
8.

Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis.

Nussbaumer B, Morgan LC, Reichenpfader U, Greenblatt A, Hansen RA, Van Noord M, Lux L, Gaynes BN, Gartlehner G.

CNS Drugs. 2014 Aug;28(8):699-712. doi: 10.1007/s40263-014-0169-z. Review.

PMID:
24794101
9.

Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.

Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN.

Ann Intern Med. 2008 Nov 18;149(10):734-50. Review.

PMID:
19017592
10.

An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder.

Thase ME, Kornstein SG, Germain JM, Jiang Q, Guico-Pabia C, Ninan PT.

CNS Spectr. 2009 Mar;14(3):144-54. Review.

PMID:
19407711
11.

Drug dose as mediator of treatment effect in antidepressant drug trials: the case of fluoxetine.

Purgato M, Gastaldon C, Papola D, Magni LR, Rossi G, Barbui C.

Acta Psychiatr Scand. 2015 Jun;131(6):408-16. doi: 10.1111/acps.12381. Review.

PMID:
25495269
12.

Newer generation antidepressants for depressive disorders in children and adolescents.

Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD004851. doi: 10.1002/14651858.CD004851.pub3. Review.

PMID:
23152227
13.

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.

Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ.

Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. Review.

PMID:
19919295
14.

Antidepressant versus placebo for depressed elderly.

Wilson K, Mottram P, Sivanranthan A, Nightingale A.

Cochrane Database Syst Rev. 2001;(2):CD000561. Review.

PMID:
11405969
15.

A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression.

Nelson JC, Baumann P, Delucchi K, Joffe R, Katona C.

J Affect Disord. 2014 Oct;168:269-75. doi: 10.1016/j.jad.2014.05.053. Review.

PMID:
25069082
16.

Fluoxetine versus other types of pharmacotherapy for depression.

Magni LR, Purgato M, Gastaldon C, Papola D, Furukawa TA, Cipriani A, Barbui C.

Cochrane Database Syst Rev. 2013 Jul 17;(7):CD004185. Review.

PMID:
24353997
17.

Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis.

Reichenpfader U, Gartlehner G, Morgan LC, Greenblatt A, Nussbaumer B, Hansen RA, Van Noord M, Lux L, Gaynes BN.

Drug Saf. 2014 Jan;37(1):19-31. doi: 10.1007/s40264-013-0129-4. Review.

PMID:
24338044
18.

Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Lozano P, Henrikson NB, Dunn J, Morrison CC, Nguyen M, Blasi PR, Anderson ML, Whitlock E.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Aug.

19.

Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials.

Naci H, Brugts JJ, Fleurence R, Ades AE.

Eur J Prev Cardiol. 2013 Aug;20(4):658-70. doi: 10.1177/2047487313483600. Review.

PMID:
23529608
20.

Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Whitlock EP, Williams SB, Burda BU, Feightner A, Beil T.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep.

Items per page

Supplemental Content

Support Center